Much of the growth was driven by contributions from Genoptix, which NeoGenomics acquired in late 2018. Organically, revenues were up 20 percent.
The partners will use the GeoMx Digital Spatial Profiler to identify new biomarkers in high-risk breast cancer and the nCounter to evaluate leukemia fusion testing.
The clearance marks the first time that the tests have been indicated to follow a new paradigm in which two enzyme immunoassay tests can be conducted concurrently or sequentially, the FDA said.
Financial analysts seemed convinced of the long-term advantages of the deal but noted that investors may remain skeptical in the near term.
The company's diagnostics segment's revenues were up 6 percent, while its discovery and analytical solutions segment's revenues grew less than 1 percent.
The Singapore-based company will debut a system at AACC that performs real-time PCR flu A/B testing in less than 20 minutes for the cost of a lateral flow test.
The Branford, Connecticut-based startup plans to seek US Food and Drug Administration clearance for and launch its instrument and first assays in 2021.
The company's total revenues were $114.1 million compared with $95.6 million in the same quarter last year, beating analysts' expectations.
Blue Shield of California's members will be able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.